Calton & Associates Inc. Invests $261,000 in GSK plc (NYSE:GSK)

Posted by on Mar 27th, 2023

Calton & Associates Inc. acquired a new position in GSK plc (NYSE:GSK – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 7,426 shares of the pharmaceutical company’s stock, valued at approximately $261,000.

A number of other hedge funds have also recently made changes to their positions in GSK. Pflug Koory LLC bought a new stake in shares of GSK in the 3rd quarter worth approximately $26,000. Northwest Investment Counselors LLC lifted its holdings in shares of GSK by 339.0% in the 4th quarter. Northwest Investment Counselors LLC now owns 777 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 600 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in shares of GSK in the 3rd quarter worth approximately $31,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the last quarter. Finally, Cowa LLC bought a new stake in shares of GSK in the 1st quarter worth approximately $45,000. 13.15% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on GSK. Bank of America downgraded shares of GSK from a “neutral” rating to an “underperform” rating in a research note on Monday, December 5th. The Goldman Sachs Group began coverage on shares of GSK in a research note on Sunday, February 26th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. lifted their target price on shares of GSK from GBX 1,350 ($16.58) to GBX 1,400 ($17.19) in a research note on Thursday, February 2nd. AlphaValue raised shares of GSK to a “buy” rating in a research note on Thursday, December 8th. Finally, Berenberg Bank lifted their target price on shares of GSK from GBX 1,580 ($19.40) to GBX 1,730 ($21.25) in a research note on Friday, February 10th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, GSK has an average rating of “Hold” and a consensus price target of $1,576.88.

GSK Stock Down 2.4 %

NYSE:GSK opened at $34.38 on Monday. The firm’s 50-day moving average price is $35.00 and its 200-day moving average price is $33.69. The company has a market capitalization of $74.11 billion, a PE ratio of 4.01, a P/E/G ratio of 1.73 and a beta of 0.65. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.91 and a quick ratio of 0.68. GSK plc has a 1-year low of $28.47 and a 1-year high of $46.97.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 13th. Investors of record on Friday, February 24th will be paid a $0.3404 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date is Thursday, February 23rd. GSK’s payout ratio is 15.50%.

GSK Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.